Published: 28 Feb 2022 | Report Code: 10248399 | Pages: 114
Asia Pacific clinical diagnostics market will grow by 9.8% annually with a total addressable market cap of $257.46 billion over 2022-2031, driven by the rising patient awareness and rising demand for high-quality care amid the COVID-19 pandemic, growing healthcare spend, technological advancement, benefits of clinical diagnostics such as quick test results and easy procedure, increasing prevalence of chronic diseases caused due to sedentary lifestyle such as diabetes, cardiovascular diseases, high blood pressure, lipid disorders, kidney diseases and cancer. Highlighted with 30 tables and 59 figures, this 114-page report “Asia Pacific Clinical Diagnostics Market 2021-2031 by Test (Lipid Panel, Infectious Disease Testing, Liver Panel, CBC), Product (Instruments, Assay Kits & Reagents, Software & Services), Indication (Cardiovascular, Cancer, Infectious Disease), Patient Gender (Male, Female), Age Group (44 and below, 45-64, 65 and over), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific clinical diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific clinical diagnostics market in every aspect of the classification from perspectives of by Test, Product, Indication, Patient Gender, Age Group, End User, and Country. Based on Test, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Lipid Panel • Infectious Disease Testing • Liver Panel • Complete Blood Count (CBC) • Electrolyte Testing • Renal Panel • Other Tests Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Instruments • Assay Kits & Reagents • Software & Services By Indication the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Cardiovascular • Cancer • Infectious Disease • Stroke • Chronic Lower Respiratory Diseases • Diabetes • Other Indications By Patient Gender the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Male Patients • Female Patients By Age Group the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Age 44 and below • Age 45-64 • Age 65 and over By End User the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Hospital & Clinics Laboratory • Diagnostic Laboratory • Point-of-Care Testing • Other End Users Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines? For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of key national markets by Test, Product, and Indication, over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: • Abbott Laboratories • Becton, Dickinson and Company • BioMerieux SA • Bio-Rad Laboratories Inc. • Bio-Reference Laboratories • Bioscientia Healthcare • Charles River Laboratories • Danaher Corporation • Hoffmann-La Roche AG • Hologic Inc. • Qiagen NV • Siemens Healthcare • Thermo Fisher Scientific (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table Of Contents:
1 Introduction 7 1.1 Industry Definition and Research Scope 7 1.1.1 Industry Definition 7 1.1.2 Research Scope 8 1.2 Research Methodology 11 1.2.1 Overview of Market Research Methodology 11 1.2.2 Market Assumption 12 1.2.3 Secondary Data 12 1.2.4 Primary Data 12 1.2.5 Data Filtration and Model Design 13 1.2.6 Market Size/Share Estimation 14 1.2.7 Research Limitations 15 1.3 Executive Summary 16 2 Market Overview and Dynamics 19 2.1 Market Size and Forecast 19 2.1.1 Impact of COVID-19 on World Economy 20 2.1.2 Impact of COVID-19 on the Market 22 2.2 Major Growth Drivers 24 2.3 Market Restraints and Challenges 30 2.4 Emerging Opportunities and Market Trends 33 2.5 Porter’s Fiver Forces Analysis 37 3 Segmentation of Asia Pacific Market by Test 41 3.1 Market Overview by Test 41 3.2 Lipid Panel 43 3.3 Infectious Disease Testing 44 3.4 Liver Panel 45 3.5 Complete Blood Count (CBC) 46 3.6 Electrolyte Testing 47 3.7 Renal Panel 48 3.8 Other Tests 49 4 Segmentation of Asia Pacific Market by Product 50 4.1 Market Overview by Product 50 4.2 Instruments 52 4.3 Assay Kits & Reagents 53 4.4 Software & Services 54 5 Segmentation of Asia Pacific Market by Indication 55 5.1 Market Overview by Indication 55 5.2 Cardiovascular 57 5.3 Cancer 58 5.4 Infectious Disease 59 5.5 Stroke 60 5.6 Chronic Lower Respiratory Diseases 61 5.7 Diabetes 62 5.8 Other Indications 63 6 Segmentation of Asia Pacific Market by Patient Gender 64 6.1 Market Overview by Patient Gender 64 6.2 Male Patients 66 6.3 Female Patients 67 7 Segmentation of Asia Pacific Market by Age Group 68 7.1 Market Overview by Age Group 68 7.2 Age 44 and below 70 7.3 Age 45-64 71 7.4 Age 65 and over 72 8 Segmentation of Asia Pacific Market by End User 73 8.1 Market Overview by End User 73 8.2 Hospital & Clinics Laboratory 75 8.3 Diagnostic Laboratory 76 8.4 Point-of-Care Testing 77 8.5 Other End Users 78 9 Asia-Pacific Market 2021-2031 by Country 79 9.1 Overview of Asia-Pacific Market 79 9.2 Japan 82 9.3 China 85 9.4 Australia 87 9.5 India 90 9.6 South Korea 92 9.7 Rest of APAC Region 94 10 Competitive Landscape 96 10.1 Overview of Key Vendors 96 10.2 New Product Launch, Partnership, Investment, and M&A 99 10.3 Company Profiles 100 Abbott Laboratories 100 Becton, Dickinson and Company 102 BioMerieux SA 103 Bio-Rad Laboratories Inc. 104 Bio-Reference Laboratories 105 Bioscientia Healthcare 106 Charles River Laboratories 107 Danaher Corporation 108 Hoffmann-La Roche AG 109 Hologic Inc. 110 Qiagen NV 111 Siemens Healthcare 112 Thermo Fisher Scientific 113 RELATED REPORTS 114
List Of Tables:
Table 1. Snapshot of Asia Pacific Clinical Diagnostics Market in Balanced Perspective, 2021-2031 17 Table 2. World Economic Outlook, 2021-2031 21 Table 3. World Health Spending by Region, $ bn, 2013-2020 29 Table 4. Main Product Trends and Market Opportunities in Asia Pacific Clinical Diagnostics Market 33 Table 5. Asia Pacific Clinical Diagnostics Market by Test, 2021-2031, $ mn 41 Table 6. Asia Pacific Clinical Diagnostics Market by Product, 2021-2031, $ mn 50 Table 7. Asia Pacific Clinical Diagnostics Market by Indication, 2021-2031, $ mn 55 Table 8. Asia Pacific Clinical Diagnostics Market by Patient Gender, 2021-2031, $ mn 64 Table 9. Asia Pacific Clinical Diagnostics Market by Age Group, 2021-2031, $ mn 68 Table 10. Asia Pacific Clinical Diagnostics Market by End User, 2021-2031, $ mn 73 Table 11. APAC Clinical Diagnostics Market by Country, 2021-2031, $ mn 80 Table 12. Japan Clinical Diagnostics Market by Test, 2021-2031, $ mn 84 Table 13. Japan Clinical Diagnostics Market by Product, 2021-2031, $ mn 84 Table 14. Japan Clinical Diagnostics Market by Indication, 2021-2031, $ mn 84 Table 15. China Clinical Diagnostics Market by Test, 2021-2031, $ mn 86 Table 16. China Clinical Diagnostics Market by Product, 2021-2031, $ mn 86 Table 17. China Clinical Diagnostics Market by Indication, 2021-2031, $ mn 86 Table 18. Australia Clinical Diagnostics Market by Test, 2021-2031, $ mn 88 Table 19. Australia Clinical Diagnostics Market by Product, 2021-2031, $ mn 88 Table 20. Australia Clinical Diagnostics Market by Indication, 2021-2031, $ mn 88 Table 21. India Clinical Diagnostics Market by Test, 2021-2031, $ mn 91 Table 22. India Clinical Diagnostics Market by Product, 2021-2031, $ mn 91 Table 23. India Clinical Diagnostics Market by Indication, 2021-2031, $ mn 91 Table 24. South Korea Clinical Diagnostics Market by Test, 2021-2031, $ mn 93 Table 25. South Korea Clinical Diagnostics Market by Product, 2021-2031, $ mn 93 Table 26. South Korea Clinical Diagnostics Market by Indication, 2021-2031, $ mn 93 Table 27. Clinical Diagnostics Market in Rest of APAC by Country/Region, 2021-2031, $ mn 95 Table 28. Abbott Laboratories: Company Snapshot 100 Table 29. Abbott Laboratories: Business Segmentation 101 Table 30. Abbott Laboratories: Product Portfolio 101
List Of Figures:
Figure 1. Research Method Flow Chart 11 Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14 Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16 Figure 4. Asia Pacific Clinical Diagnostics Market, 2021-2031, $ mn 19 Figure 5. Impact of COVID-19 on Business 22 Figure 6. Primary Drivers and Impact Factors of Asia Pacific Clinical Diagnostics Market 24 Figure 7. Leading Causes of Death in the World, 2019-2020, million 27 Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 28 Figure 9. World Population 65 and Over, % of Total Population, 1950-2060 28 Figure 10. Primary Restraints and Impact Factors of Asia Pacific Clinical Diagnostics Market 30 Figure 11. Investment Opportunity Analysis 34 Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Clinical Diagnostics Market 37 Figure 13. Breakdown of Asia Pacific Clinical Diagnostics Market by Test, 2021-2031, % of Revenue 42 Figure 14. Asia Pacific Addressable Market Cap in 2022-2031 by Test, Value ($ mn) and Share (%) 42 Figure 15. Asia Pacific Clinical Diagnostics Market by Test: Lipid Panel, 2021-2031, $ mn 43 Figure 16. Asia Pacific Clinical Diagnostics Market by Test: Infectious Disease Testing, 2021-2031, $ mn 44 Figure 17. Asia Pacific Clinical Diagnostics Market by Test: Liver Panel, 2021-2031, $ mn 45 Figure 18. Asia Pacific Clinical Diagnostics Market by Test: Complete Blood Count (CBC), 2021-2031, $ mn 46 Figure 19. Asia Pacific Clinical Diagnostics Market by Test: Electrolyte Testing, 2021-2031, $ mn 47 Figure 20. Asia Pacific Clinical Diagnostics Market by Test: Renal Panel, 2021-2031, $ mn 48 Figure 21. Asia Pacific Clinical Diagnostics Market by Test: Other Tests, 2021-2031, $ mn 49 Figure 22. Breakdown of Asia Pacific Clinical Diagnostics Market by Product, 2021-2031, % of Sales Revenue 51 Figure 23. Asia Pacific Addressable Market Cap in 2022-2031 by Product, Value ($ mn) and Share (%) 51 Figure 24. Asia Pacific Clinical Diagnostics Market by Product: Instruments, 2021-2031, $ mn 52 Figure 25. Asia Pacific Clinical Diagnostics Market by Product: Assay Kits & Reagents, 2021-2031, $ mn 53 Figure 26. Asia Pacific Clinical Diagnostics Market by Product: Software & Services, 2021-2031, $ mn 54 Figure 27. Breakdown of Asia Pacific Clinical Diagnostics Market by Indication, 2021-2031, % of Sales Revenue 56 Figure 28. Asia Pacific Addressable Market Cap in 2022-2031 by Indication, Value ($ mn) and Share (%) 56 Figure 29. Asia Pacific Clinical Diagnostics Market by Indication: Cardiovascular, 2021-2031, $ mn 57 Figure 30. Asia Pacific Clinical Diagnostics Market by Indication: Cancer, 2021-2031, $ mn 58 Figure 31. Asia Pacific Clinical Diagnostics Market by Indication: Infectious Disease, 2021-2031, $ mn 59 Figure 32. Asia Pacific Clinical Diagnostics Market by Indication: Stroke, 2021-2031, $ mn 60 Figure 33. Asia Pacific Clinical Diagnostics Market by Indication: Chronic Lower Respiratory Diseases, 2021-2031, $ mn 61 Figure 34. Asia Pacific Clinical Diagnostics Market by Indication: Diabetes, 2021-2031, $ mn 62 Figure 35. Asia Pacific Clinical Diagnostics Market by Indication: Other Indications, 2021-2031, $ mn 63 Figure 36. Breakdown of Asia Pacific Clinical Diagnostics Market by Patient Gender, 2021-2031, % of Revenue 65 Figure 37. Asia Pacific Addressable Market Cap in 2022-2031 by Patient Gender, Value ($ mn) and Share (%) 65 Figure 38. Asia Pacific Clinical Diagnostics Market by Patient Gender: Male Patients, 2021-2031, $ mn 66 Figure 39. Asia Pacific Clinical Diagnostics Market by Patient Gender: Female Patients, 2021-2031, $ mn 67 Figure 40. Breakdown of Asia Pacific Clinical Diagnostics Market by Age Group, 2021-2031, % of Revenue 69 Figure 41. Asia Pacific Addressable Market Cap in 2022-2031 by Age Group, Value ($ mn) and Share (%) 69 Figure 42. Asia Pacific Clinical Diagnostics Market by Age Group: Age 44 and below, 2021-2031, $ mn 70 Figure 43. Asia Pacific Clinical Diagnostics Market by Age Group: Age 45-64, 2021-2031, $ mn 71 Figure 44. Asia Pacific Clinical Diagnostics Market by Age Group: Age 65 and over, 2021-2031, $ mn 72 Figure 45. Breakdown of Asia Pacific Clinical Diagnostics Market by End User, 2021-2031, % of Revenue 73 Figure 46. Asia Pacific Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 74 Figure 47. Asia Pacific Clinical Diagnostics Market by End User: Hospital & Clinics Laboratory, 2021-2031, $ mn 75 Figure 48. Asia Pacific Clinical Diagnostics Market by End User: Diagnostic Laboratory, 2021-2031, $ mn 76 Figure 49. Asia Pacific Clinical Diagnostics Market by End User: Point-of-Care Testing, 2021-2031, $ mn 77 Figure 50. Asia Pacific Clinical Diagnostics Market by End User: Other End Users, 2021-2031, $ mn 78 Figure 51. Breakdown of APAC Clinical Diagnostics Market by Country, 2021 and 2031, % of Revenue 80 Figure 52. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 81 Figure 53. Clinical Diagnostics Market in Japan, 2021-2031, $ mn 83 Figure 54. Clinical Diagnostics Market in China, 2021-2031, $ mn 85 Figure 55. Clinical Diagnostics Market in Australia, 2021-2031, $ mn 87 Figure 56. Clinical Diagnostics Market in India, 2021-2031, $ mn 90 Figure 57. Clinical Diagnostics Market in South Korea, 2021-2031, $ mn 92 Figure 58. Clinical Diagnostics Market in Rest of APAC, 2021-2031, $ mn 94 Figure 59. Growth Stage of Asia Pacific Clinical Diagnostics Industry over the Forecast Period 96
Selected Key Players: • Abbott Laboratories • Becton, Dickinson and Company • BioMerieux SA • Bio-Rad Laboratories Inc. • Bio-Reference Laboratories • Bioscientia Healthcare • Charles River Laboratories • Danaher Corporation • Hoffmann-La Roche AG • Hologic Inc. • Qiagen NV • Siemens Healthcare • Thermo Fisher Scientific (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)